Radiotherapy and Androgen Deprivation In Combination After Local Surgery

Conditions

Prostate cancer Cancer Prostate cancer

Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, Petersen PM, Persad RA, Pugh CA, Saad F, Logue J, Payne H, Bower LC, Brawley C, Rauchenberger M, Barkati M, Bottomley DM, Brasso K, Chung HT, Chung PWM, Conroy R, Falconer A, Ford V, Goh CL, Heath CM, James ND, Kim-Sing C, Kodavatiganti R, Malone SC, Morris SL, Nabid A, Ong AD, Raman R, Rodda S, Wells P, Worlding J, Parulekar WR, Parmar MKB, Sydes MR, RADICALS investigators.

2024-05-1635 citations

10.1016/s0140-6736(24)00549-x

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.

Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, Anderson J, Barkati M, Bottomley DM, Branagan J, Choudhury A, Chung PWM, Cogley L, Goh CL, Hoskin P, Khoo V, Malone SC, Masters L, Morris SL, Nabid A, Ong AD, Raman R, Tarver KL, Tree AC, Worlding J, Wylie JP, Zarkar AM, Parulekar WR, Parmar MKB, Sydes MR, RADICALS investigators.

2024-05-1623 citations

10.1016/s0140-6736(24)00548-8

Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047).

Parker CC, Petersen PM, Cook AD, Clarke NW, Catton C, Cross WR, Kynaston H, Parulekar WR, Persad RA, Saad F, Bower L, Durkan GC, Logue J, Maniatis C, Noor D, Payne H, Anderson J, Bahl AK, Bashir F, Bottomley DM, Brasso K, Capaldi L, Chung C, Cooke PW, Donohue JF, Eddy B, Heath CM, Henderson A, Henry A, Jaganathan R, Jakobsen H, James ND, Joseph J, Lees K, Lester J, Lindberg H, Makar A, Morris SL, Oommen N, Ostler P, Owen L, Patel P, Pope A, Popert R, Raman R, Ramani V, Røder A, Sayers I, Simms M, Srinivasan V, Sundaram S, Tarver KL, Tran A, Wells P, Wilson J, Zarkar AM, Parmar MKB, Sydes MR, RADICALS investigators.

2024-04-0530 citations

10.1016/j.annonc.2024.03.010

Interventions

Current interventions as of 15/09/2014: Radiotherapy timing randomisation: Arm 1A: adjuvant radiotherapy (RT) to prostate bed Arm 1B: observation policy with early salvage RT to prostate bed given in

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patient has undergone radical prostatectomy

Exclusion criteria

Exclusion criteria: 1. Androgen deprivation prior to radical prostatectomy 2. Bilateral orchidectomy 3. Prior pelvic radiotherapy 4. Other active malignancy likely to interefere with protocol treatment or follow-up 5. Known distant metastases from prostate cancer

Design outcomes

Primary

Measure	Time frame
Disease-specific survival (i.e., death due to prostate cancer)	—

Secondary

Measure	Time frame
1. Freedom from treatment failure 2. Clinical progression-free survival 3. Overall survival 4. Non-protocol androgen deprivation 5. Quality of life 6. Treatment toxicity	—

Countries

Canada, Denmark, England, Ireland, United Kingdom

Outcome results

None listed